Herpes Labialis: An Update.

IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics
Alexander K C Leung, Benjamin Barankin
{"title":"Herpes Labialis: An Update.","authors":"Alexander K C Leung,&nbsp;Benjamin Barankin","doi":"10.2174/1872213X11666171003151717","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Herpes labialis is characterized by recurrent vesicular eruptions primarily on the lips and perioral skin. The condition is contagious, can cause significant discomfort/pain, and can have an adverse effect on the quality of life.</p><p><strong>Objective: </strong>To update the evaluation and treatment of herpes labialis.</p><p><strong>Methods: </strong>A PubMed search was completed in Clinical Queries using the key term \"herpes labialis\". Patents were searched using the key term \"herpes labialis\" from www.freepatentsonline.com.</p><p><strong>Results: </strong>The diagnosis of herpes labialis is mainly clinical based on classic grouped lesions (papules, vesicles, ulcers) on the lip. Antiviral therapy shortens the duration of pain and discomfort, hastens healing, and reduces viral shedding. Thus, episodic treatment is warranted, especially if the patient desires treatment for cosmetic purposes or for relief of pain. Such treatment needs to be initiated promptly, ideally in the prodromal stage and no later than 48 hours from the onset of lesions to achieve optimal results. Chronic suppressive therapy with oral antiviral agents should be considered for patients with severe or frequent (six or more episodes per year) recurrences. Recent patents related to the management of herpes labialis are also discussed.</p><p><strong>Conclusion: </strong>For episodic treatment, oral antiviral agents, such as acyclovir (Zovirax), valacyclovir (Valtrex) and famciclovir (Famvir), are superior to topical antiviral therapy. Valacyclovir and famciclovir have greater oral bioavailability and are better absorbed than acyclovir, require less frequent dosing, but are more expensive and are not approved for children. Topical antiviral agents such as 5% acyclovir cream/ointment (Zovirax) ± hydrocortisone (Xerese), 1% penciclovir (Denavir) cream, and 50 mg Buccal Adhesive Tablet (ABT-50 mg) can also be used for episodic treatment of herpes labialis. These topical agents are not effective in the prevention of recurrent herpes labialis. For chronic daily suppressive therapy, oral antivirals are the treatment of choice.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on inflammation & allergy drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872213X11666171003151717","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 19

Abstract

Background: Herpes labialis is characterized by recurrent vesicular eruptions primarily on the lips and perioral skin. The condition is contagious, can cause significant discomfort/pain, and can have an adverse effect on the quality of life.

Objective: To update the evaluation and treatment of herpes labialis.

Methods: A PubMed search was completed in Clinical Queries using the key term "herpes labialis". Patents were searched using the key term "herpes labialis" from www.freepatentsonline.com.

Results: The diagnosis of herpes labialis is mainly clinical based on classic grouped lesions (papules, vesicles, ulcers) on the lip. Antiviral therapy shortens the duration of pain and discomfort, hastens healing, and reduces viral shedding. Thus, episodic treatment is warranted, especially if the patient desires treatment for cosmetic purposes or for relief of pain. Such treatment needs to be initiated promptly, ideally in the prodromal stage and no later than 48 hours from the onset of lesions to achieve optimal results. Chronic suppressive therapy with oral antiviral agents should be considered for patients with severe or frequent (six or more episodes per year) recurrences. Recent patents related to the management of herpes labialis are also discussed.

Conclusion: For episodic treatment, oral antiviral agents, such as acyclovir (Zovirax), valacyclovir (Valtrex) and famciclovir (Famvir), are superior to topical antiviral therapy. Valacyclovir and famciclovir have greater oral bioavailability and are better absorbed than acyclovir, require less frequent dosing, but are more expensive and are not approved for children. Topical antiviral agents such as 5% acyclovir cream/ointment (Zovirax) ± hydrocortisone (Xerese), 1% penciclovir (Denavir) cream, and 50 mg Buccal Adhesive Tablet (ABT-50 mg) can also be used for episodic treatment of herpes labialis. These topical agents are not effective in the prevention of recurrent herpes labialis. For chronic daily suppressive therapy, oral antivirals are the treatment of choice.

唇疱疹:最新进展。
背景:唇疱疹的特点是主要在嘴唇和口周皮肤上反复出现水疱性皮疹。这种情况会传染,会引起严重的不适/疼痛,并对生活质量产生不利影响。目的:提高对唇疱疹的认识和治疗水平。方法:在PubMed的临床查询中,以“唇疱疹”为关键词进行检索。使用关键词“唇疱疹”从www.freepatentsonline.com.Results检索专利:唇疱疹的诊断主要基于唇上的经典分组病变(丘疹,囊泡,溃疡)。抗病毒治疗缩短疼痛和不适的持续时间,加速愈合,减少病毒脱落。因此,间歇治疗是必要的,特别是如果患者希望治疗美容目的或缓解疼痛。这种治疗需要及时开始,最好是在前驱期开始,不迟于病变发生后48小时,以达到最佳效果。对于复发严重或频繁(每年6次或以上)的患者,应考虑口服抗病毒药物进行慢性抑制治疗。最近的专利有关的管理唇疱疹也进行了讨论。结论:对于间歇治疗,口服抗病毒药物如阿昔洛韦(Zovirax)、valacyclovir (Valtrex)和famciclovir (Famvir)优于局部抗病毒治疗。Valacyclovir和famciclovir具有更高的口服生物利用度,比阿昔洛韦吸收更好,给药频率更低,但价格更高,并且未被批准用于儿童。局部抗病毒药物,如5%阿昔洛韦乳膏/软膏(Zovirax)±氢化可的松(Xerese), 1%喷昔洛韦(地那韦)乳膏和50毫克口腔胶粘剂(ABT-50毫克)也可用于发作性唇疱疹的治疗。这些局部药物对预防复发性唇疱疹无效。对于慢性每日抑制治疗,口服抗病毒药物是治疗的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
0.00%
发文量
0
期刊介绍: Recent Patents on Inflammation & Allergy Drug Discovery publishes review articles by experts on recent patents in the field of inflammation and allergy drug discovery e.g. on novel bioactive compounds, analogs and targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in inflammation and allergy drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信